jdiane, you're half right.
At the conferences 4, 5, 6 years ago, they were indeed recommending "monotherapy" (meaning just Remicade). The scattered cases of HSTCL were scary, even to docs. There wasn't enough clear data at the time about
the risks/benefits of combination therapy for them to recommend it, and the cases of HSTCL made them be very cautious and just recommend Remicade on its own.
They made it quite clear this year that they have accumulated so much more data in the last 4 years and that it points to using combination therapy, because it has a definite benefit over monotherapy and very little increased risk of anything (with the exception of young males)..
And they also emphasized, again, that these meds are safer than prednisone, by far. Yet so many IBDers take pred and don't worry about
it, while at the same time they're afraid of Remicade. The data shows pred to be much more dangerous, statistically speaking.